COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway

COMPASS Pathways plc

2023-Q1 EPS reported -$0.57

Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.
Cash $117.1M at March 31, 2023; raised additional $26.9M net via ATM in Q2.
Phase 3 pivotal trials (COMP 005, COMP 006) in TRD underway; top-line data expected summer 2024 and mid-2025.
CPT III code for psychedelic therapy support accepted by AMA, effective Jan 1, 2024.
FY 2023 net cash used in operating activities guidance $85M-$110M; Q2 guidance $22M-$30M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COMPASS Pathways plc reported the three months ended March 31, 2023 results: net income $24.2 million, EPS $0.57 loss per share.

Period: the three months ended March 31, 2023
Net income: $24.2 million
EPS: $0.57 loss per share
Result: reported results

Exact text from the filing

Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001628280-23-017392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.